Pfizer (NYSE:PFE) Shares Up 1.7% – What’s Next?

Pfizer Inc. (NYSE:PFE)’s share price was up 1.7% during mid-day trading on Friday . The stock traded as high as $27.13 and last traded at $27.07. Approximately 52,753,648 shares were traded during mid-day trading, an increase of 11% from the average daily volume of 47,559,922 shares. The stock had previously closed at $26.61.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug (Xianweiying / ecnoglutide), opening a large new market for its obesity franchise and reinforcing Pfizer’s push into metabolic drugs — this expands addressable market and supports long‑term revenue potential. China approves Pfizer GLP-1 drug for weight management
• Positive Sentiment: Analyst upgrade: Argus Research upgraded PFE to Buy and set a $35 target, citing progress in the GLP‑1 program and oncology pipeline — this can attract buy interest and boost sentiment among dividend and income investors. Argus Turns Bullish on Pfizer
• Positive Sentiment: Oncology wins: positive Phase 3 EV‑304 PADCEV results and FDA full approval for BRAFTOVI combinations were highlighted as re‑framing Pfizer’s long‑term growth prospects in oncology — supports diversification away from COVID revenues. Pfizer Obesity Nod In China And Cancer Wins
• Positive Sentiment: Pipeline expansion in China: Pfizer launched a Phase 1 heart‑failure candidate study in China, signaling continued local R&D investment that could yield future launches in a large market. Pfizer Adds New Early-Stage Heart Failure Candidate
• Neutral Sentiment: Investor attention & valuation debate: multiple articles note heightened retail/institutional interest and divergent valuation views (trending stock coverage, DCF vs. long‑term return debates) — increases volatility/volume but not a direct fundamental change. Pfizer Is a Trending Stock
• Neutral Sentiment: Competition & generics risk for GLP‑1s: coverage notes Pfizer will face crowded competition (and price pressure risk) even as it gains approvals — a mixed commercial outlook. Weight-Loss Drug Approved in China — Up Against Generic Rivals
• Negative Sentiment: Structural headwinds remain: analysts reiterate risks from declining COVID revenues, upcoming patent expirations and U.S. drug‑pricing pressures (IRA) that could limit near‑term growth despite new launches. Can Pfizer Reignite Growth?
• Negative Sentiment: Policy/legal noise: a recent court ruling awarded Pfizer $29M in an SEC settlement dispute (one‑time benefit), but legal and policy developments remain sources of uncertainty for investors. Judge approves Pfizer, SEC settlement

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PFE. TD Cowen restated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Wolfe Research set a $24.00 price target on Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. UBS Group assumed coverage on Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price objective for the company. Finally, Morgan Stanley lowered their target price on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $28.05.

Pfizer Stock Performance

The business has a 50-day moving average of $26.26 and a 200 day moving average of $25.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The company has a market cap of $153.93 billion, a PE ratio of 19.90 and a beta of 0.47.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the previous year, the company posted $0.63 EPS. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. Equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 126.47%.

Institutional Investors Weigh In On Pfizer

A number of hedge funds have recently modified their holdings of the business. Fiduciary Alliance LLC boosted its stake in Pfizer by 46.4% during the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after buying an additional 46,043 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Pfizer in the 3rd quarter worth about $3,019,000. Money Concepts Capital Corp lifted its holdings in shares of Pfizer by 29.9% in the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after acquiring an additional 57,188 shares during the last quarter. Vista Investment Partners LLC boosted its stake in shares of Pfizer by 236.1% during the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after purchasing an additional 48,900 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. grew its holdings in Pfizer by 76.4% during the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock valued at $2,784,000 after purchasing an additional 47,319 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.